Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Rebecca Robertson as Chair of its Board of Directors, effective immediately. Ms. Robertson, who joined the Board in January 2019, takes over from Kim Blickenstaff, who remains a Board member. The transition comes as the company seeks to enhance its leadership during a pivotal growth phase. CEO John Sheridan and Blickenstaff praised Robertson for her valuable insights and experience in medical devices. With a strong background in scaling medical companies, Robertson expressed her commitment to advancing Tandem's innovative solutions for diabetes care. The company continues to develop a promising product pipeline.
Tandem Diabetes Care (NASDAQ: TNDM) announced its financial results for Q4 and the full year 2022, highlighting a 14% increase in worldwide GAAP sales to $801.2 million and a 15% increase in non-GAAP sales to $804.8 million. The company reported a 29% growth in its customer base, totaling approximately 420,000. However, a GAAP operating loss of $92.8 million was noted for the year. In terms of guidance for 2023, TNDM expects non-GAAP sales between $885 million and $900 million, representing a growth of 10-12%. The firm also acquired AMF Medical SA, enhancing its product portfolio.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in several upcoming investor conferences. Key presentations will take place at the Citi Healthcare Services Conference on March 2, Cowen Healthcare Conference on March 6, Raymond James Conference on March 8, Oppenheimer Healthcare Conference on March 13, and Barclays Global Healthcare Conference on March 14. Each presentation will be webcast live, with an archive available for 30 days on their Investor Center website. Tandem Diabetes focuses on innovative insulin delivery solutions, including the t:slim X2 insulin pump.
Tandem Diabetes Care (NASDAQ:TNDM) has completed its acquisition of AMF Medical SA, the Swiss developer of the Sigi™ Patch Pump, which focuses on simplifying diabetes management. The Sigi Patch Pump is still under development and not yet commercially available. The acquisition aligns with Tandem's strategy to enhance its product offerings, bringing in AMF's innovative technology and experienced team. With a mission to improve diabetes care, Tandem aims to leverage this technology to better serve its customers.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its fourth quarter and full year 2022 financial results on February 22, 2023, after the market closes. A conference call is scheduled for 4:30 PM Eastern Time to discuss the results, which will be accessible via a webcast on their Investor Center website. The company emphasizes innovation in insulin delivery, particularly with its t:slim X2 insulin pump featuring Control-IQ technology, aimed at improving diabetes management. Further details will be available post-event on the website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced its preliminary sales results for Q4 2022, reporting GAAP sales of $221 million, up from $210 million in Q4 2021. For the full year, GAAP sales reached $802 million, increasing from $703 million in 2021. The company expects a worldwide sales growth of 11-12% in 2023, not including new product launches like the Mobi Insulin Pump, under FDA review. The CEO highlighted strong customer retention and satisfaction for their t:slim X2 Insulin Pump.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will present an update on Wednesday, January 11, 2023, at 8:15 PM Eastern Time. The presentation will be available via a live webcast, with an archived recording accessible for 30 days on the company’s Investor Center website. Tandem Diabetes Care focuses on innovative insulin delivery solutions and is known for its t:slim X2 insulin pump featuring Control-IQ technology.
Tandem Diabetes Care (TNDM) has announced its definitive agreement to acquire AMF Medical, the Swiss developer of the Sigi™ Patch Pump. This acquisition is expected to expand Tandem's addressable market for insulin delivery solutions and enhance its product portfolio. The deal includes an initial payment of CHF 62.4 million, in addition to contingent earnout payments totaling up to CHF 129.6 million based on milestone achievements. The acquisition aims to accelerate product development, reduce waste, and offer additional customer access, with the transaction expected to close in January 2023.
Tandem Diabetes Care (NASDAQ: TNDM) has achieved the Great Place to Work Certification, with 84% of employees affirming it’s a great workplace, significantly higher than the national average. This recognition, based on employee feedback, highlights Tandem's commitment to a positive workplace culture, aligning with its core value of People First. The company has gained local accolades in San Diego and Boise for its work environment, emphasizing its focus on employee satisfaction.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced positive results from a multicenter study on the t:slim X2 insulin pump featuring Control-IQ technology for type 2 diabetes management. The study found significant improvements in glycemic control, with a 15% increase in time in range (3.6 hours/day). No hypoglycemia was reported. High satisfaction levels were observed among participants. The trial involved 30 adults across three centers. Notably, Control-IQ technology is not yet FDA-approved for type 2 diabetes use and was employed under an investigational device exemption.